- Home
- AKYA vs CRDL Comparison
AKYA vs CRDL Comparison
Compare AKYA & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKYA
- CRDL
- Stock Information
- Founded
- AKYA 2015
- CRDL 2017
- Country
- AKYA United States
- CRDL Canada
- Employees
- AKYA N/A
- CRDL N/A
- Industry
- AKYA Medical Specialities
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKYA Industrials
- CRDL Health Care
- Exchange
- AKYA Nasdaq
- CRDL Nasdaq
- Market Cap
- AKYA 145.5M
- CRDL 125.7M
- IPO Year
- AKYA 2021
- CRDL N/A
- Fundamental
- Price
- AKYA $2.49
- CRDL $1.28
- Analyst Decision
- AKYA Buy
- CRDL Strong Buy
- Analyst Count
- AKYA 7
- CRDL 3
- Target Price
- AKYA $4.40
- CRDL $9.00
- AVG Volume (30 Days)
- AKYA 382.0K
- CRDL 389.6K
- Earning Date
- AKYA 11-14-2024
- CRDL 11-14-2024
- Dividend Yield
- AKYA N/A
- CRDL N/A
- EPS Growth
- AKYA N/A
- CRDL N/A
- EPS
- AKYA N/A
- CRDL N/A
- Revenue
- AKYA $86,815,000.00
- CRDL N/A
- Revenue This Year
- AKYA N/A
- CRDL N/A
- Revenue Next Year
- AKYA $11.76
- CRDL N/A
- P/E Ratio
- AKYA N/A
- CRDL N/A
- Revenue Growth
- AKYA N/A
- CRDL N/A
- 52 Week Low
- AKYA $1.88
- CRDL $0.79
- 52 Week High
- AKYA $6.31
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- AKYA 51.92
- CRDL 26.78
- Support Level
- AKYA $2.20
- CRDL $1.27
- Resistance Level
- AKYA $2.63
- CRDL $1.46
- Average True Range (ATR)
- AKYA 0.23
- CRDL 0.10
- MACD
- AKYA 0.05
- CRDL -0.00
- Stochastic Oscillator
- AKYA 68.66
- CRDL 3.33
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.